Researchers conducted a retrospective cohort study of 114 patients (68% female; median age at onset, 8.3 years; 92% White) with juvenile localized scleroderma from the National Registry for Childhood ...
Clinical enrollment for an open-label, single-arm Phase 1/2 trial of FCX-013 was initiated in August 2018. Fibrocell Science announced that the Food and Drug Administration (FDA) has granted Fast ...
Padua, Italy - Although juvenile localized scleroderma is typically thought of as a skin disease, Dr Francesco Zulian reports in the September 2005 issue of Arthritis & Rheumatism that 22.4% of ...
Fibrocell Science has submitted an Investigational New Drug Application (IND) with the FDA for a gene therapy candidate to treat moderate to severe localized scleroderma. Fibrocell Science has ...
EXTON, Pa., Oct. 15, 2020 /PRNewswire/ -- Castle Creek Biosciences, Inc, a privately-held, clinical-stage cell and gene therapy company leveraging its proprietary fibroblast technology platform to ...
Scleroderma is a range of disorders in which the skin and connective tissues tighten and harden. It is a long-term, progressive disease. This means it gradually gets worse. Share on Pinterest ...
DANVERS, Mass.--(BUSINESS WIRE)--The Scleroderma Foundation, a national nonprofit that advances medical research, promotes disease awareness and provides support and education to people with ...
The advertiser paid a fee to promote this sponsored article and may have influenced or authored the content. The views expressed in this article are those of the advertiser and do not necessarily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results